selenoprotein IGenealiases: EPT1 · SELI · SEPI · SPG81
Q-omics provides the consensus-scored SELENOI profile across patient tissues and cancer cell-line models. SELENOI expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SELENOI is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SELENOI protein abundance shows 21,918 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BLCA, and LSCC as cancer lineages where SELENOI shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SELENOI — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SELENOI survival associations across molecular data types. SELENOI RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SELENOI RNA expression–survival associations across cancer types. High SELENOI expression shows unfavorable associations in MESO, ACC, UCEC, BLCA and UVM, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SELENOI RNA expression.
This table summarizes SELENOI tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SELENOI. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SELENOI shows higher tumor expression in BLCA, LUAD, HNSC, STAD, LUSC and COAD. The BLCA box plot shows higher SELENOI RNA expression in tumor versus normal tissue (log2 FC = +2.081, t-test p < 0.001).
This table shows molecular features associated with SELENOI in patient tissues and cancer cell lines. In patient samples, SELENOI shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SELENOI RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
